Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer. Mollica V, Rosellini M, Santoni M, Massari F, et al. Eur Urol 2026 Oct 7:S0302-2838(26)02409-7. doi: 10.1016/j.eururo.2026.

Read + Share

Amedeo Smart

Independent Medical Education

Mollica V, Rosellini M, Santoni M, Massari F, et al. Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer. Eur Urol 2026 Oct 7:S0302-2838(26)02409-7. doi: 10.1016/j.eururo.2026.
PMID: 42844113